Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
Myelodysplastic syndromes are characterized by ineffective hematopoiesis in one or more lineages of the bone marrow. They are a group of heterogeneous clonal stem cell malignancies with a high risk to progress to acute myeloid leukemia. Currently, there are no curative FDA-approved medications for m...
Saved in:
Main Authors: | Waqas Jehangir, Alexander Karabachev, Taimoor Jahangir, Elvira Umyarova |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2020/9031067 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes
by: Ioannis Koutsavlis
Published: (2016-01-01) -
Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome
by: Maha A. Badawi, et al.
Published: (2010-01-01) -
Myelodysplastic Syndrome and Autoimmunity: A Case Report of an Unusual Presentation of Myelodysplastic Syndrome
by: Andrea L. Merrill, et al.
Published: (2011-01-01) -
Iron Chelation Therapy in Myelodysplastic Syndromes
by: Emanuela Messa, et al.
Published: (2010-01-01) -
Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
by: Ethan A. Natelson, et al.
Published: (2013-01-01)